Valuation: Intellipharmaceutics International Inc.

Market Cap 1.41M 1.21M 1.13M 1.03M 1.95M 134M 1.96M 13.41M 5.2M 67.67M 5.28M 5.17M 224M P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 3.65M 3.13M 2.94M 2.68M 5.07M 348M 5.09M 34.79M 13.48M 176M 13.7M 13.4M 581M EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.15
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 2007-03-31
Corporate Officer/Principal - 2014-01-31
Director TitleAgeSince
Director/Board Member - 2004-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-3.59%-7.10%+61.60%+114.83% 1,100B
-1.15%-1.25%+52.98%+62.41% 658B
-1.09%-1.15%+26.18%+79.22% 470B
-1.47%+0.24%+42.09%+42.09% 372B
-0.90%+0.05%+25.57%+41.75% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.43%-0.46%+52.06%+71.75% 239B
-0.93%+1.84%-13.11%-52.28% 213B
-0.46%+0.33%+29.05%+92.67% 184B
Average -1.20%+0.15%+31.05%+51.74% 380.29B
Weighted average by Cap. -1.82%-1.58%+40.53%+68.24%

Financials

2021 2022
Net sales - 65.73K 56.41K 52.95K 48.36K 91.27K 6.27M 91.71K 627K 243K 3.16M 247K 241K 10.48M
Net income -5.15M -4.42M -4.14M -3.79M -7.14M -491M -7.18M -49.05M -19.01M -248M -19.32M -18.9M -820M -2.89M -2.48M -2.33M -2.13M -4.02M -276M -4.04M -27.58M -10.69M -139M -10.86M -10.62M -461M
Net Debt 1.15M 983K 923K 843K 1.59M 109M 1.6M 10.92M 4.23M 55.11M 4.3M 4.21M 183M 2.24M 1.92M 1.81M 1.65M 3.11M 214M 3.13M 21.38M 8.28M 108M 8.42M 8.24M 357M
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
  1. Stock Market
  2. Stocks
  3. IPCI.Q Stock